Literature DB >> 25447422

Nanoscale drug delivery for taxanes based on the mechanism of multidrug resistance of cancer.

Shengpeng Wang1, Jiange Qiu2, Zhi Shi3, Yitao Wang1, Meiwan Chen4.   

Abstract

Taxanes are one type of the most extensively used chemotherapeutic agents to treat cancers. However, their clinical use is severely limited by intrinsic and acquired resistance. A diverse variety of mechanisms has been implicated about taxane resistance, such as alterations of drug targets, overexpression of efflux transporters, defective apoptotic machineries, and barriers in drug transport. The deepening understanding of molecular mechanisms of taxane resistance has spawned a number of targets for reversing resistance. However, circumvention of taxane resistance would not only possess therapeutic potential, but also face with clinical challenge, which accelerates the development of optimal nanoscale delivery systems. This review highlights the current understanding on the mechanisms of taxane resistance, and provides a comprehensive analysis of various nanoscale delivery systems to reverse taxane resistance.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cancer; Multidrug resistance; Nanoparticles; Taxanes

Mesh:

Substances:

Year:  2014        PMID: 25447422     DOI: 10.1016/j.biotechadv.2014.10.011

Source DB:  PubMed          Journal:  Biotechnol Adv        ISSN: 0734-9750            Impact factor:   14.227


  9 in total

1.  Low-dose paclitaxel downregulates MYC proto-oncogene bHLH transcription factor expression in colorectal carcinoma cells.

Authors:  Wenjing Li; Wanyun Zhu; Chaoxiang Lv; Hao Qu; Kaixiang Xu; Honghui Li; Haifeng Li; Yiming Du; Guangming Liu; Yunyue Wang; Hong-Jiang Wei; Hong-Ye Zhao
Journal:  Oncol Lett       Date:  2017-12-05       Impact factor: 2.967

Review 2.  Predictive value of BRCA1 expression on the efficacy of chemotherapy based on anti-microtubule agents: a pooled analysis across different malignancies and agents.

Authors:  Qihua He; Mingzhe Zhang; Jianrong Zhang; Shengyi Zhong; Yang Liu; Jianfei Shen; Jiaxi He; Long Jiang; Chenglin Yang; Yuan Zeng; Minzhang Guo; Xuewei Chen; Jianxing He; Wenhua Liang
Journal:  Ann Transl Med       Date:  2016-03

3.  The critical size of gold nanoparticles for overcoming P-gp mediated multidrug resistance.

Authors:  Yuqian Jiang; Zheng Wang; Wei Duan; Lingyan Liu; Mahan Si; Xiaoyuan Chen; Chen-Jie Fang
Journal:  Nanoscale       Date:  2020-06-17       Impact factor: 7.790

4.  YM155 enhances docetaxel efficacy in ovarian cancer.

Authors:  Li-Jiao Hou; Xiao-Xiu Huang; Li-Na Xu; Yan-Yan Zhang; Na Zhao; Rong-Ying Ou; Wen-Feng Li; Wen-Ji Zhang; Qi-Wei Jiang; Yang Yang; Meng-Ning Wei; Jia-Rong Huang; Kun Wang; Meng-Ling Yuan; Zi-Hao Xing; Zhi Shi; Xiao-Jian Yan
Journal:  Am J Transl Res       Date:  2018-03-15       Impact factor: 4.060

5.  Cell-penetrating peptide conjugates to enhance the antitumor effect of paclitaxel on drug-resistant lung cancer.

Authors:  Ziqing Duan; Cuitian Chen; Jing Qin; Qi Liu; Qi Wang; Xinchun Xu; Jianxin Wang
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

6.  Tumor-selective peptide-carrier delivery of Paclitaxel increases in vivo activity of the drug.

Authors:  Jlenia Brunetti; Serena Pillozzi; Chiara Falciani; Lorenzo Depau; Eleonora Tenori; Silvia Scali; Luisa Lozzi; Alessandro Pini; Annarosa Arcangeli; Stefano Menichetti; Luisa Bracci
Journal:  Sci Rep       Date:  2015-12-02       Impact factor: 4.379

7.  Schisandrin B reverses doxorubicin resistance through inhibiting P-glycoprotein and promoting proteasome-mediated degradation of survivin.

Authors:  Shengpeng Wang; Anqi Wang; Min Shao; Ligen Lin; Peng Li; Yitao Wang
Journal:  Sci Rep       Date:  2017-08-21       Impact factor: 4.379

8.  Balancing the stability and drug activation in adaptive nanoparticles potentiates chemotherapy in multidrug-resistant cancer.

Authors:  Jianqin Wan; Lingling Huang; Jiangting Cheng; Huangfu Qi; Jiahui Jin; Hangxiang Wang
Journal:  Theranostics       Date:  2021-02-19       Impact factor: 11.556

Review 9.  Endogenous pH-responsive nanoparticles with programmable size changes for targeted tumor therapy and imaging applications.

Authors:  Wei Wu; Li Luo; Yi Wang; Qi Wu; Han-Bin Dai; Jian-Shu Li; Colm Durkan; Nan Wang; Gui-Xue Wang
Journal:  Theranostics       Date:  2018-04-30       Impact factor: 11.556

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.